Article Text

Download PDFPDF

PreImplantation factor (PIF) potentiates static magnetic field (SMF) effect to decrease tumor burden (melanoma murine model)
  1. Beatrix Kotlan1,2,
  2. Janos F Laszlo3,
  3. Jozsef Tovari4,
  4. Miklos Kasler5,6 and
  5. Eytan Barnea7,8
  1. Aff1 grid.419617.c0000000106678064Molecular Immunology and ToxicologyNational Institute of Oncology Budapest Hungary
  2. Aff2 grid.419617.c0000000106678064Surgical and Molecular TumorpathologyNational Institute of Oncology Budapest Hungary
  3. Aff3 grid.7122.60000000110888582Applied Mathematics and Probability TheoryUniversity of Debrecen, Faculty of Informatics Debrecen Hungary
  4. Aff4 grid.419617.c0000000106678064Experimental PharmacologyNational Institute of Oncology Budapest Hungary
  5. Aff5 grid.419617.c0000000106678064Board of DirectorsNational Institute of Oncology Budapest Hungary
  6. Aff6 Univ Medicine and Pharmacy Tirgu Mures Romania
  7. Aff7 grid.430199.6Society for the Investigation of Early Pregnancy Cherry Hill NJ USA
  8. Aff8 BioIncept LLC Cherry Hill NJ USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts

Background and objectives

PreImplantation factor (PIF) secreted by viable embryos exerts essential regulatory role on global systemic immune response. Synthetic PIF (PIF) translates endogenous effects to immune disorder models. Metastatic melanoma displays tumor-immunological behaviour. Static magnetic field (SMF) affects inflammatory reactions. There is increased interest toward SMF’s potential anti-tumor effects. Herein examined a novel anti-melanoma strategy using combined physical and immune-based therapy.


Daily whole-body SMF exposure, combined with subcutaneous PIF administration was examined in engrafted HT199 melanoma cells’ progression, transplanted into NSG mice. PIF effect on unique tumor-associated antigen expression relevant for tumor proliferation/ invasion was examined in vitro using specific antibodies. Direct PIF anti-proliferative effects on several cancer cell lines were tested using MTT.


PIF potentiates SMF beneficial effect by reducing tumor volume vs. control (Mmax=96%) on day 34. Metastatic spleen mass is reduced by SMF alone (M=59%) or combined with PIF (M=62%). Daily SMF exposure alone inhibits tumor outgrowth (Mmax=60%, F5.32 (P<0.002)=21.16) while in combination with PIF, effect is considerably potentiated (M=80%), F5.32(P<0.0004)=34.84). PIF did not impair tumor antigen expression nor reduced significantly cultured tumor cell lines’ proliferation.


Collectively, results indicate that PIF’s potentiating anti-tumoral effect is mainly immune-regulatory, synergizing with SMF’s pro-tumor necrosis properties. The preserved tumor-associated antigen expression is important for the maintained antitumor immune activity. Overall, combined physico / immune regulatory treatment represents a useful, promising novel avenue for anti-cancer strategy.


Harry J Loyd Charitable Trust Melanoma Research Award, INNO 08-3-2009-0248, BioIncept LLC - PIF proprietary.